Axsome Therapeutics (AXSM) Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Which has more risk & volatility, JAZZ or AXSM?

Jazz Pharmaceuticals has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Does the media prefer JAZZ or AXSM?

In the previous week, Axsome Therapeutics had 3 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 19 mentions for Axsome Therapeutics and 16 mentions for Jazz Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 1.40 beat Jazz Pharmaceuticals' score of 1.36 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	12 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Axsome Therapeutics	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer JAZZ or AXSM?

Jazz Pharmaceuticals currently has a consensus target price of $178.67, suggesting a potential upside of 40.57%. Axsome Therapeutics has a consensus target price of $177.86, suggesting a potential upside of 47.77%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.88
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.13

Which has stronger valuation & earnings, JAZZ or AXSM?

Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.07B	1.89	$560.12M	-$6.73	-18.89
Axsome Therapeutics	$385.69M	15.57	-$287.22M	-$5.07	-23.74

Is JAZZ or AXSM more profitable?

Jazz Pharmaceuticals has a net margin of -9.91% compared to Axsome Therapeutics' net margin of -49.88%. Jazz Pharmaceuticals' return on equity of 5.02% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	-9.91%	5.02%	1.73%
Axsome Therapeutics	-49.88%	-283.22%	-33.06%

Do institutionals & insiders believe in JAZZ or AXSM?

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 22.3% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.